jzp541
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2023 (NCT05733390)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Anandamide amidohydrolaseINHIBITOR
FAAH inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06014424 | Phase 2 | Sep 27, 2023 | University of Toronto |
| NCT05733390 | Phase 2 | Jun 30, 2023 | GW Research, Jazz Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GW Research | For profit | 1 | 0 | 1 | 2023 |
| Jazz Pharmaceuticals | For profit | 1 | 1 | 1 | 2023 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1